Combination Chemotherapy in Treating Young Patients With Hodgkin's Lymphoma

• Status: Completed
• Trial end date: 2013-01-01
• Target enrollment: 0
• Participant gender: All

Summary

RATIONALE: Drugs used in chemotherapy work in different ways to stop the growth of cancer cells, either by killing the cells or by stopping them from dividing. Giving more than one drug (combination chemotherapy) may kill more cancer cells. It is not yet known which combination chemotherapy regimen is more effective in treating Hodgkin's lymphoma.

PURPOSE: This randomized phase III trial is studying different combination chemotherapy regimens to compare how well they work in treating young patients with Hodgkin's lymphoma.

• Phase: Phase 3
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Christine Mauz-Körholz
• Collaborators: Deutsche Krebshilfe e.V., Bonn (Germany); Euronet Worldwide
• Treatments: Cyclophosphamide; Dacarbazine; Fluorodeoxyglucose F18; Prednisolone; Prednisone; Procarbazine; Vincristine

Criteria

DISEASE CHARACTERISTICS:

• Histologically confirmed classical Hodgkin's lymphoma

• No lymphocyte-predominant Hodgkin's lymphoma

• Fine-needle biopsy not sufficient

• No prior treatment for Hodgkin's lymphoma except for recommended pre-phase therapy for a large mediastinal tumor

PATIENT CHARACTERISTICS:

• No known hypersensitivity or contraindication to study drugs

• No other current malignancy

• No severe concurrent disease (e.g., immune deficiency syndrome)

• Not pregnant or nursing

• Fertile patients must use effective contraception during and for up to 1 year after completion of study treatment

• No known HIV positivity

PRIOR CONCURRENT THERAPY:

• See Disease Characteristics

• No prior chemotherapy or radiotherapy

• At least 30 days since prior and no other concurrent investigational drugs or participation in another investigational trial